12:00 AM
Jan 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Orvepitant: Phase II started

Researchers began the double-blind, U.S. Phase II COPE trial to compare 60 mg/day oral orvepitant vs. placebo for 12 weeks in 240 patients.

GlaxoSmithKline plc...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >